 Home > Active Ingredient News > Study of Nervous System > Idiopathic narcolepsy drug Xywav oral solution receives priority review by the U.S. FDA

Idiopathic narcolepsy drug Xywav oral solution receives priority review by the U.S. FDA

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

pch drug

analog drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Jazz Pharmaceuticals announced that the FDA has accepted Xywav oral solution for the treatment of adult patients with idiopathic narcolepsy as a supplementary new drug application for substantive review.

If approved, Xywav will be the first and only drug in the United States to treat adult patients with IH.

IH is a chronic neurological disease characterized by excessive sleepiness, uncontrollable sleep requirements, or daytime sleepiness that lasts for at least 3 months, even when sleep is adequate or prolonged at night.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.